Fernand Labrie

Publications

Page 5 of 25, showing 50 records out of 1234 total, starting on record 201, ending on 250

Publication Category Year
1034. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. All publications 2001
1033. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. All publications 2001
1032. Barbier, O., Albert, C., Martineau, I., Vallée, M., High, K., Labrie, F., Hum, D.W., Labrie, C., Bélanger, A. (2003) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068) by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol, 59: 636-45. All publications 2001
1031. Dufort, I., Labrie, F., Luu-The, V. (2001) Human types 1 and 3 3?-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J. Clin. Endocrinol. Metab., 86: 841-846. All publications 2001
1030. Labrie, F. (2001) Prostate cancer: Endocrinology of prostate cancer - intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Endocrinology and Metabolism, pp 13-16. All publications 2001
1029. Luu-The, V., Dufort, I., Pelletier, G., Labrie, F. (2001) Type 5 17β-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol. Cell. Endocrinol., 171: 77-82. All publications 2001
1028. Zhu, D.-W., Cantin, L., Nahoum, V., Rehse, P., Luu-The, V., Labrie, F., Breton, R., Lin, S.-X. (2001) Crystallization and preliminary X-ray crystallographic analysis of the human type 3 3β-hydroxysteroid dehydrogenase at 1.8 Å resolution. Acta Crystallogr. D., D57: 589-591. All publications 2001
1027. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Bodzioch, M., Teare, D., Ford, D., Dearnaley, D., Ardern-Jones, A., Labrie, F. (2001) High risk genes predisposing to prostate cancer development-do they exist? Prostate cancer and prostatic diseases, 3: 241-247. All publications 2001
1026. Pelletier, G., Li, S., Luu-The, V., Tremblay, Y., Bélanger, A., Labrie, F. (2001) Immunoelectron microscopic localization of three key steroidogenic enzymes (cytochrome P450scc, 3β-hydroxysteroid dehydrogenase and cytochrome P450c17) in rat adrenal cortex and gonads. J Endocrinology, 171: 373-383. All publications 2001
1025. Pelletier, G., Labrie, C., Martel, C., Li, S., Labrie, F. (2001) Role of extra-ovarian estrogens in the regulation of GnRH mRNA expression in the rat brain. J. Neuroendocrinol, 13: 678-682. All publications 2001
1024. Nahoum, V., Gangloff, A., Legrand, P., Zhu, D.-W., Cantin, L., Zhorov, B., Luu-The, V., Labrie, F., Breton, R., Lin, S.-X. (2001) Structure of the human 3 alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25 a resolution. J. of Biological Chemistry, 276: 41091-98. All publications 2001
1023. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2001) Prostate Cancer Screening: The Only Way to Early Treatment and a Major Impact on Survival. Proceeding of the VIIth International Congress of Andrology, 461-468. All publications 2001
1022. Labrie, F. (2001) Unique role of hormone therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate cancer: biology, diagnosis and management, pp 301-314. All publications 2001
1021. Labrie, F. (2001) The Role of Androgen Therapy in Postmenopausal Women - Physiology of Androgens in Women. Supplement to Menopause Management, 11: 3-5. All publications 2001
1020. Brawer, M.K., Crawford, E.D., Labrie, F., Mendoza-Valdz, A., Miller, P.D., Petrylak, D.P. (2001) Androgen deprivation and other treatments for advanced prostate cancer. Reviews in Urology, 3: S59-S68. All publications 2001
1019. Labrie, F. (2001) Dehydroepiandrosterone (DHEA) as potential hormone replacement therapy. Références en Gynecologie Obstétrique, 8: 317-322. All publications 2001
1018. Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R.E., Lévesque, J., Brousseau, G., Bélanger, A., Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 45: 19-35. All publications 2000
1017. El-Alfy, M., Pelletier, G. Hermo, L.S., Labrie, F. (2000) Unique features of the basal cells of human prostate epithelium. Microsc. Res. Tech., 51: 436-446. All publications 2000
1016. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. All publications 2000
1015. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. All publications 2000
1014. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. All publications 2000
1013. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. All publications 2000
1012. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor β and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. All publications 2000
1011. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. All publications 2000
1010. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. All publications 2000
1009. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. All publications 2000
1008. Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., El Alfy, M. (2000) Intracrinology and the skin. Horm. Res., 54: 218-229. All publications 2000
1007. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. All publications 2000
1006. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. All publications 2000
1005. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. All publications 2000
1004. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. All publications 2000
1003. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. All publications 2000
1002. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. All publications 2000
1001. The BRCA1 Exon 13 Duplication Screening Group. (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet., 67: 207-212. All publications 2000
1000. Boivin, R.P., Luu-The, V., Lachance, R., Labrie, F., Poirier, D. (2000) Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J. Med. Chem., 43: 4465-4478. All publications 2000
999. Mauriège, P., Langin, D., Montminy, V., Martel, C., Després, J.P., Bélanger, A., Labrie, F., Deshaies, Y. (2000) Effect of a long-term percutaneous adrenal steroid treatment on rat adipose tissue metabolism. Int. J. Obes. Relat. Metab. Disord., 24: S148-S150. All publications 2000
998. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (2000) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: (DHEA): Biochemical Physiological and Clinical Aspects, pp 191-213. All publications 2000
997. Sam, K.-M., Labrie, F., Poirier, D. (2000) N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17β-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur. J. Med. Chem., 35: 217-225. All publications 2000
996. Singh, S.M., Gauthier, S., Labrie, F. (2000) Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem., 7: 211-247. All publications 2000
995. Tatchum-Talom, R., Martel, C., Labrie, C., Labrie, F., Marette, A. (2000) Gender differences in hemodynamic responses to endothelin-1. J. Cardiovasc. Pharmacol, 36: S102-S104. All publications 2000
994. Labrie, F. (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer trialists' Collaborative Group. Lancet, 355: 1491-8. All publications 2000
993. Gyomorey, S., Gupta, S., Lye, S.J., Gibb, W., Labrie, F., Challis, J.R.G. (2000) Temporal expression of prostaglandin H synthase type 2 (PGHS-2) and P450c17 in ovine placentomes with the natural onset of labour. Placenta, 21: 478-486. All publications 2000
992. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. All publications 1999
991. Kelloff, G.J., Lieberman, R., Brawer, M.K., Crawford, E.D., Labrie, F., Miller, G.J. (1999) Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostatic Diseases, 2: 27-33. All publications 1999
990. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. All publications 1999
989. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. All publications 1999
988. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. All publications 1999
987. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. All publications 1999
986. Labrie, F., Candas, B. (1999) The Quebec study shows a 69% decrease in prostate cancer death [Authors' Response to comment of Alexander and Prescott on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 137. All publications 1999
985. Labrie, F., Candas, B. (1999) Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial [Authors' Response to comment of Boer and Schroder on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 132-134. All publications 1999
<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards